Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bionxt Solutions Inc (OP: XPHYF )

N/A UNCHANGED
Last Price Updated: 3:44 PM EST, Dec 21, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bionxt Solutions Inc

< Previous 1 2 3 Next >
BioNxt Reports Update on Commercialization of Rotigotine Patch for Treatment of Parkinson's Disease
Via ACCESSWIRE
InvestorNewsBreaks – BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: XPHYF) (FSE: 4XT) to Expand Portfolio with Precision Drug Delivery Technology
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
BioNxt Solutions Signs Term Sheet for Novel Precision Drug Coating Platform Technology
Via ACCESSWIRE
InvestorNewsBreaks – BioNxt Solutions Inc. (CSE: BNXT) (OTCQB: XPHYF) (FSE: 4XT) Holds Key Meetings, Advances Product at Frankfurt CPHI Conference
Via Investor Brand Network
Topics Supply Chain
Exposures COVID-19 Supply Chain
BioNxt Solutions Reports on Frankfurt CPHI Conference
Via ACCESSWIRE
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Changes Name to BioNxt Solutions Inc.
Via Investor Brand Network
XPhyto Announces Name Change to BioNxt Solutions Inc.
Via ACCESSWIRE
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Major Milestone on Path to Commercialization of Lead Product
Via Investor Brand Network
XPhyto Reports Excellent Rotigotine In-Vitro/Ex-Vivo Results for Parkinson's Disease Treatment
Via ACCESSWIRE
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Completion of Rotigotine TDS Patch Study
Via Investor Brand Network
XPhyto Completes Rotigotine Transdermal Patch Optimization and Comparative Skin Absorption Study
Via ACCESSWIRE
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Inks LOI to Identify Manufacturing, Strategic Business Opportunities
Via Investor Brand Network
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Patent Application for Novel Psychedelic Compound Library
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Exploring Expanded Application of ODF Screening Tests
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Congratulates Dr. Raimar Loebenberg as Recipient of 2022 CSPS Award
Via Investor Brand Network
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Expands European Team to Add Pharmaceutical Manufacturing Expert
Via Investor Brand Network
Exposures Product Safety
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Reports Positive Results of Rotigotine Transdermal Patch Study
Via Investor Brand Network
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Provides Update on Market, Product Development of Key Biosensor
Via Investor Brand Network
XPhyto, Biosensors Market and Product Developments on Platform-Based Oral Dissolvable Biosensors for Oral Health and Infectious Disease
VANCOUVER, BC and UTTENWEILER, GERMANY / ACCESSWIRE / April 11, 2022 / XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) ("XPhyto" or the "Company") is pleased to provide a market and product... 
From XPhyto Therapeutics Corp.
Via AccessWire
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Update on Rotigotine Transdermal Patch Development
Via Investor Brand Network
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Closes First Tranche of Private Placement
Via Investor Brand Network
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Updates on Psychedelic Medicine Programs Progess, Novel Compounds Milestone
Via Investor Brand Network
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Issues Update Regarding Its Three Primary Business Divisions
Via Investor Brand Network
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces New Covid-ID Lab Sales Contracts
Via Investor Brand Network
Exposures COVID-19
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Provides Update on Integration of 3a-diagnostics GmbH
Via Investor Brand Network
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Appoints European Head of Sales
Via Investor Brand Network
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Inks Czech Republic Distribution Deal, Announces Rollout Plan for Additional European Territories
Via Investor Brand Network
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces Strategic Appointments
Via Investor Brand Network
Exposures COVID-19
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Announces January 2022 Commencement of Epilepsy Clinical Trial
Via Investor Brand Network
InvestorNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Completes Transformative Step in Commercial Strategy with 3a Acquisition
Via Investor Brand Network
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.